Home > Insider Trading > Filing (0001127602-11-016473)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
882796	Biocryst Pharmaceuticals Inc	BCRX	Biological Products, (No Disgnostic Substances) (2836)	621413174

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1518724	Peder Jensen	4505 Emperor Blvd. Suite 200 Durham NC 27703		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-05-12	10,000	$3.56	10,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option	Acquisiton	2011-05-12	15,000	$0.00	15,000	$3.56
Common Stock	Non-Qualified Stock Option	Acquisiton	2011-05-12	7,917	$0.00	7,917	$3.56

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000	2011-06-13	2021-05-12	No	4	A	Direct
7,917	2011-06-13	2021-05-12	No	4	A	Direct

Footnotes

Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (the "Plan").
The option vests 1/12 per month for a period of 12 months, beginning on June 13, 2011.
The reporting person began service on the board of directors of BioCryst Pharmaceuticals, Inc. (the "Company") effective May 3, 2011, in advance of the Company's annual meeting, at the request of the Company's board of directors. Under the Plan, each non-employee director receives an automatic option grant to purchase 25,000 shares, prorated based on the number of months remaining until the Company's next annual meeting, at the time of his or her initial election or appointment to the Company's board of directors. On May 3, 2011, the reporting person was granted an option to purchase 2,083 shares. Had the reporting person joined the board of directors on the date of the annual meeting, May 12, 2011, he would have received an automatic option grant to purchase 25,000 shares. As permitted under the Plan, the reporting person was granted this discretionary option to purchase 7,917 shares, which, combined with the previous option grant of 2,083 shares and the automatic grant of 15,000 shares reported on this Form 4, totals 25,000 shares, to avoid an inequitable loss of shares due to timing.